NEWARK, NJ--(Marketwired - December 12, 2013) - BioNeutral Group, Inc. (OTCBB: BONU) (OTCQB: BONU) today announced that it has entered into a product distribution agreement with BioTech Medical Inc. (BTM), a manufacturer and national distributor of products to medical facilities, federal government agencies and cost containment organizations.
The new agreement will allow BioNeutral to drive a deeper relationship with our YGIENE™ and OGIENE™ lines into the health care marketplace.
Andrea L. Goren, Executive Director of BioTech Medical, Inc., said, "According to the EPA (Environmental Protection Agency) 100% of all types of mold have the potential to cause harmful health effects. This can be minor to severe and even death in some rare cases. YGIENE 206 is the first product we have found that kills ALL types of mold in less than five-minutes. In fact, compared with traditional antimicrobial agents, YGIENE 206 has superior efficacy, reduced toxicity and is labeled by the EPA as a cleaner, disinfectant, and sterilant. A sterilant kills all forms of microbial life on inanimate environmental surfaces." Ms. Goren closes by saying, "We are passionate about raising health standards through the identification and distribution of new and innovative infection control technologies and BioNeutral has proved to be strides ahead of their competition."
Ray Dunning, Sr. Vice President of Sales, commented, "BioNeutral is very excited to be working with an organization like BioTech Medical with their reach to over 1,000 customers and distributors. BioTech Medical is well respected in our industry and has a sales team that possesses the professionalism and technical knowledge required to bring our new technologies to the medical marketplace."
About BioTech Medical Inc.
BioTech Medical, Inc. is a North Canton, Ohio based subsidiary of privately-held Suarez Corporation Industries (SCI), a leading international marketing company. SCI distributes hundreds of diversified products around the world and has established its success through product innovation and multi-channel marketing. BioTech Medical's multiple business segments are each focused on the distribution of innovative healthcare products, all natural cleaning technologies, and antimicrobial solutions for a wide variety of commercial applications, including the groundbreaking "combinational chemistry" featured in BioNeutral Group's revolutionary YGIENE™ and OGIENE™ technologies. You can find BioTech Medical, Inc. at www.biotechmedicalllc.com
About BioNeutral Group, Inc.
Headquartered in Newark, New Jersey, BioNeutral Group, Inc. is a specialty technology-based life-science company that has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, YGIENE™ and OGIENE™ kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the YGIENE™ brand have been approved by the EPA for sale in the United States and has previously been approved for sale in Germany and it is also permitted to be sold in the UK, France and Sweden. Auto Neutral is a registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutral.com.
Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393
Follow us on Twitter: http://twitter.com/bioneutralgroup
Forward-Looking Statements: This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to YGIENE-206. BioNeutral's antimicrobial formulations will be marketed under the brand name YGIENE™ and are available for sale in the United States.